Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455

被引:27
|
作者
Wu, Daichao [1 ]
Guo, Ming [1 ]
Philips, Michael A. [2 ]
Qu, Lingzhi [1 ]
Jiang, Longying [1 ]
Li, Jun [1 ]
Chen, Xiaojuan [1 ]
Chen, Zhuchu [1 ]
Chen, Lin [1 ,2 ]
Chen, Yongheng [1 ,2 ,3 ]
机构
[1] Cent S Univ, Struct Biol Lab, Key Lab Canc Prote, Chinese Minist Hlth,XiangYa Hosp, Changsha 410008, Hunan, Peoples R China
[2] Univ Southern Calif, Dept Biol Sci, Mol & Computat Biol, Los Angeles, CA 90089 USA
[3] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
来源
PLOS ONE | 2016年 / 11卷 / 09期
基金
中国国家自然科学基金;
关键词
FACTOR RECEPTOR 4; HUMAN BREAST; GROWTH; INHIBITOR; POTENT; MUTATIONS; XENOGRAFT; AZD4547; BINDING; FAMILY;
D O I
10.1371/journal.pone.0162491
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant FGFR4 signaling has been documented abundantly in various human cancers. The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3. However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM. To date, there is no published crystal structure of LY2874455 in complex with any kinase. To better understand the pan-FGFR selectivity of LY2874455, we have determined the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resolution of 2.35 angstrom. LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a number of van der Waals contacts. After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP-binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs. Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.
引用
收藏
页数:11
相关论文
共 11 条
  • [1] Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
    Darwis, Narisa Dewi Maulany
    Horigome, Eisuke
    Li, Shan
    Adachi, Akiko
    Oike, Takahiro
    Shibata, Atsushi
    Hirota, Yuka
    Ohno, Tatsuya
    CELLS, 2022, 11 (11)
  • [2] Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
    Hanes, Robert
    Munthe, Else
    Grad, Iwona
    Han, Jianhua
    Karlsen, Ida
    McCormack, Emmet
    Meza-Zepeda, Leonardo A.
    Stratford, Eva Wessel
    Myklebost, Ola
    CELLS, 2019, 8 (02)
  • [3] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael
    Yung-Jue Bang
    Young Suk Park
    Yoon-Koo Kang
    Tae Min Kim
    Oday Hamid
    Donald Thornton
    Sonya C. Tate
    Eyas Raddad
    Jeanne Tie
    Targeted Oncology, 2017, 12 : 463 - 474
  • [4] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael, Michael
    Bang, Yung-Jue
    Park, Young Suk
    Kang, Yoon-Koo
    Kim, Tae Min
    Hamid, Oday
    Thornton, Donald
    Tate, Sonya C.
    Raddad, Eyas
    Tie, Jeanne
    TARGETED ONCOLOGY, 2017, 12 (04) : 463 - 474
  • [5] Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
    Dehghanian, Fariba
    Alavi, Shahryar
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
    Fariba Dehghanian
    Shahryar Alavi
    Scientific Reports, 11
  • [7] LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
    Wu, Daichao
    Guo, Ming
    Min, Xiaoli
    Dai, Shuyan
    Li, Meixiang
    Tan, Sijie
    Li, Guoqing
    Chen, Xiaojuan
    Ma, Yao
    Li, Jun
    Jiang, Longying
    Qu, Lingzhi
    Zhou, Zhan
    Chen, Zhuchu
    Chen, Lin
    Xu, Guangyu
    Chen, Yongheng
    CHEMICAL COMMUNICATIONS, 2018, 54 (85) : 12089 - 12092
  • [8] FGFR1 gene amplification predicts the antitumor response of FGFR inhibitor LY2874455 in human lung cancer cells
    Bi, Chen
    Zhao, Genshi
    Baker, Jessica A.
    Starling, James J.
    Wu, Wenjuan
    CANCER RESEARCH, 2012, 72
  • [9] Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
    Kim, Sun Young
    Ahn, Taejin
    Bang, Heejin
    Ham, Jun Soo
    Kim, Jusun
    Kim, Seung Tae
    Jang, Jiryeon
    Shim, Moonhee
    Kang, So Young
    Park, Se Hoon
    Min, Byung Hoon
    Lee, Hyuk
    Kang, Won Ki
    Kim, Kyoung-Mee
    Park, Woongyang
    Lee, Jeeyun
    ONCOTARGET, 2017, 8 (09) : 15014 - 15022
  • [10] LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
    Liu, Dongcheng
    Liu, Hongguang
    Gan, Jiadi
    Zeng, Shinuan
    Zhong, Fuhua
    Zhang, Bin
    Zhang, Zhe
    Zhang, Siyu
    Jiang, Lu
    Wang, Guangsuo
    Chen, Yixin
    Kong, Feng-Ming Spring
    Fang, Wenfeng
    Wang, Lingwei
    FRONTIERS IN PHARMACOLOGY, 2022, 13